DHS Just Banned Imports From China's Biggest Genomics Companies, and Your Sequencing Data's Supply Chain Just Got Political
By Dakota Jones
Desk: Political & Government, Public Policy & Regulatory
ANCHOR: A sequencing instrument is not just a box on a laboratory bench. It is a product with parts, suppliers and a path through customs. That path just became more politically charged.
The Department of Homeland Security has added three Chinese genomics companies to the Uyghur Forced Labor Prevention Act Entity List. The measure takes effect October 29, 2026. U.S. Customs and Border Protection will now presume that goods produced by the listed entities were made with forced labor, and bar their entry unless importers can meet the law’s requirements to rebut that presumption.
The companies are BGI Genomics Co., Ltd., MGI Tech Co., Ltd., and Shenzhen BGI Technology Co., Ltd., also known as BGI Group.
That is a major change for companies importing genomics-related goods. It is not, however, an order banning every sequencing service, every laboratory instrument already in the country, or every genetic-data file. The legal action is about goods produced by the listed entities and their entry into the United States. That distinction matters. So does the paperwork.
What DHS announced, and what the rule does
What you’ll learn: Who is affected, what CBP’s presumption means, and why “banned imports” needs a little legal fine print.
DHS announced the action on October 28, on behalf of the Forced Labor Enforcement Task Force, or FLETF. The UFLPA Entity List now contains 190 entities, following the addition of 43 entities on July 31, 2026.
Under the law, CBP applies a rebuttable presumption to goods produced by listed entities: the goods are treated as made with forced labor and are prohibited from entering the United States unless the importer provides the evidence required to overcome that presumption.
In plain English, the importer carries the burden. It is no longer enough to say a shipment has a supplier invoice and a confident-looking tracking number. Importers need to establish where the goods came from and satisfy the legal standard with clear evidence.
The designation does not mean every product or activity associated with genomics is automatically prohibited. It does mean that supply-chain checks involving these named entities have immediate significance for covered imports. The precise answer for a particular shipment depends on its facts and the law, not on a vague assurance that somebody, somewhere, checked a box.
The companies and the government’s stated basis
What you’ll learn: How the three companies relate to one another and what DHS says underlies the designation.
DHS describes the companies as related. Shenzhen BGI Technology is the controlling shareholder of BGI Genomics. MGI Tech is under the control of the same ultimate controlling shareholder as BGI Group.
The government says the companies supported genetic-testing programs in Xinjiang alongside the regional government. DHS and FLETF say the programs helped facilitate surveillance and repression of ethnic minorities and were connected to forced-labor practices. The government also cited sourcing links to Xinjiang in its Entity List rationale for BGI Genomics and Shenzhen BGI Technology.
Those are the government’s findings and allegations underlying the action. They should be reported as such, not quietly upgraded into a claim that every product from every related company has been individually proven to involve forced labor.
China’s commerce ministry condemned the move. BGI Genomics also issued a statement in response to its inclusion. Neither response changes the immediate compliance rule: CBP’s presumption takes effect October 29.
Why sequencing supply chains are now in the story
What you’ll learn: Why this is relevant beyond the customs desk, and what the designation does not directly decide.
Genomics companies supply sequencing equipment, reagents, services and related technology used around the world, including in U.S. research and healthcare settings. That makes the policy consequential well beyond a narrow debate about trade paperwork.
A life-sciences buyer may be focused on performance, price and delivery time. A customs agency is also asking who produced the goods, where inputs originated, and whether the importer can support its claims. Those questions can meet at the same loading dock.
But let’s keep the scope straight: the Entity List action governs the importation of covered goods. It does not, by itself, announce a blanket shutdown of all U.S. research involving sequencing, or a direct ban on every dataset connected to these companies. The practical exposure is in the supply chain: identifying covered goods, tracing their origin and documenting a lawful basis for entry.
For research organizations, healthcare providers and their suppliers, that makes vendor due diligence a governance issue, not just an administrative chore. A purchase order can look routine right up until a shipment reaches the border and someone asks for evidence.
What importers and buyers should do next
What you’ll learn: Practical steps to put the announcement on your compliance team’s radar.
- Check supplier and manufacturer identities. Review purchasing and import records for the three listed entities, including related-company names. Do not rely only on a brand name or distributor.
- Trace the shipment. Identify the producer, relevant inputs and supply-chain records for goods that may be covered.
- Preserve supporting documentation. Make sure the evidence behind sourcing and origin claims is organized and available, not scattered across inboxes, vendors and a spreadsheet last updated during a different administration.
- Escalate uncertain shipments. Ask qualified trade-compliance or legal professionals to assess whether a particular product and transaction fall within the rule and what evidence CBP requires.
- Coordinate across teams. Procurement, research, clinical operations, logistics and compliance may each hold a different piece of the record. Bring them together before the shipment is on the clock.
This is a practical checklist, not legal advice. Importers should consult current DHS and CBP guidance and qualified counsel about specific shipments.
A wider enforcement signal
DHS also said its joint DHS-DOJ Trade Fraud Task Force had realized more than $1 billion in penalties, recoveries and charged losses during its first year. That is the department’s reported figure, and it places this action within a broader enforcement push.
For companies that treat trade compliance as a last-minute customs form, the signal is fairly clear: enforcement is part of the operating environment now. Supply-chain claims need evidence behind them.
For readers in Rockville, Washington, D.C., and the wider Maryland research corridor, the story is especially easy to recognize as a local question with global inputs. That does not establish that any particular local institution is affected. It does underline why organizations with research and healthcare supply chains should know who made what they import.
At LD3 Productions, our news reporting focuses on fact-based storytelling and trust-building journalism. You can learn more about our approach and production services.
FAQ
Are imports from all three companies banned?
Goods produced by the listed entities are subject to the UFLPA’s rebuttable presumption and are barred from U.S. entry unless importers meet the legal requirements to rebut it. The action is not a blanket ban on all genomics products from all manufacturers.
Does the action ban sequencing data?
The announced action concerns goods produced by the listed entities and their importation. It is not a direct, general ban on sequencing data.
When does the designation take effect?
CBP applies the presumption effective October 29, 2026.
Who has to provide evidence?
The importer must meet the applicable legal requirements to rebut the presumption for covered goods.
Final Thoughts
The headline is dramatic. The compliance reality is specific: three named companies, a UFLPA Entity List designation, and a new evidentiary burden for importers of covered goods.
If your organization buys genomics equipment or related products, start with supplier identity, origin records and shipment documentation. Do not assume a familiar product category makes the supply chain simple, or that a reassuring vendor email is the same thing as clear evidence.
The sequencing supply chain has become a geopolitical flashpoint. The best response is not panic. It is a careful review, backed by records that can stand up to scrutiny.
Sources: